SCHEMBL30795877

SCHEMBL30795877

Cc1ccc2c(c1)C(c1ccccc1)N(C(=O)CCC(=O)NCCc1ccccc1)CC2

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
ALDH1A1 P00352 3/20 0.47
NPC1 O15118 1/20 0.47
MITF O75030 1/20 0.47
XBP1 P17861 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HHAT Q5VTY9 4/20 0.45
KIF11 P52732 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
CYP2D6 P10635 1/20 0.44
TAAR1 Q96RJ0 1/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.42
STAT3 P40763 1/20 0.42
TRPV1 Q8NER1 1/20 0.41
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3238899 1.00 LMNA (0.47) LMNAALDH1A1NPC1MITFXBP1
SCHEMBL30794971 0.90 HHAT (0.49) LMNAALDH1A1NPC1MITFXBP1
SCHEMBL3242927 0.90 HHAT (0.49) LMNAALDH1A1NPC1MITFXBP1
SCHEMBL30824707 0.90 PKM (0.49) LMNAALDH1A1NPC1MITFXBP1
SCHEMBL3231197 0.90 PKM (0.49) LMNAALDH1A1NPC1MITFXBP1
SCHEMBL30795973 0.88 HHAT (0.54) LMNAALDH1A1NPC1MITFXBP1
SCHEMBL3242998 0.88 HHAT (0.54) LMNAALDH1A1NPC1MITFXBP1
SCHEMBL3237106 0.86 LMNA (0.46) LMNAALDH1A1NPC1MITFXBP1
SCHEMBL30794541 0.86 LMNA (0.46) LMNAALDH1A1NPC1MITFXBP1
SCHEMBL30794387 0.84 PKM (0.44) LMNAALDH1A1NPC1MITFXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed